Comparison 1.
Prophylactic platelet transfusion at a standard trigger level versus a higher trigger level
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Numbers of participants with a significant bleeding event | 3 | 499 | Risk Ratio (M-H, Fixed, 95% CI) | 1.35 [0.95, 1.90] |
| 1.1 Platelet threshold < 10 vs. < 20 | 2 | 333 | Risk Ratio (M-H, Fixed, 95% CI) | 1.41 [0.95, 2.10] |
| 1.2 Platelet threshold < 10 vs. < 30 | 1 | 166 | Risk Ratio (M-H, Fixed, 95% CI) | 1.19 [0.59, 2.37] |
| 2 Number of participants with WHO Grade 3 or 4 bleeding | 2 | 421 | Risk Ratio (M-H, Fixed, 95% CI) | 0.99 [0.52, 1.88] |
| 2.1 Platelet threshold < 10 vs. < 20 | 1 | 255 | Risk Ratio (M-H, Fixed, 95% CI) | 1.21 [0.58, 2.54] |
| 2.2 Platelet threshold < 10 vs. < 30 | 1 | 166 | Risk Ratio (M-H, Fixed, 95% CI) | 0.55 [0.14, 2.13] |
| 3 Number of participants with bleeding requiring a red cell transfusion | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 4 Time to first bleeding episode | 1 | Hazard Ratio (Fixed, 95% CI) | Subtotals only | |
| 5 All-cause mortality | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 6 Mortality due to bleeding | 3 | Risk Ratio (M-H, Fixed, 95% CI) | Totals not selected | |
| 7 Mortality due to bleeding (all randomised participants) | 3 | Odds Ratio (M-H, Fixed, 95% CI) | Totals not selected | |
| 8 Mortality due to infection | 1 | Odds Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 9 Mean number of platelet transfusions per participant | 2 | 333 | Mean Difference (IV, Fixed, 95% CI) | −2.09 [−3.20, −0.99] |
| 10 Mean number of red cell transfusions per participant | 2 | 333 | Mean Difference (IV, Fixed, 95% CI) | 0.66 [−0.43, 1.76] |
| 11 Complete remission rates | 2 | 333 | Risk Ratio (M-H, Fixed, 95% CI) | 0.92 [0.78, 1.09] |
| 12 Numbers of participants with platelet transfusion reactions | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 13 Number of participants with thromboembolic disease | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 14 Number of participants requiring HLA-matched platelets | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 15 Number of participants with platelet refractoriness | 2 | 244 | Risk Ratio (M-H, Fixed, 95% CI) | 0.66 [0.16, 2.67] |
| 16 Numbers of participants with a significant bleeding event | 3 | 499 | Risk Ratio (M-H, Fixed, 95% CI) | 1.35 [0.95, 1.90] |
| 16.1 Platelet component dose (2.9 × 1011 to 4.9 × 1011) | 2 | 244 | Risk Ratio (M-H, Fixed, 95% CI) | 1.71 [1.04, 2.82] |
| 16.2 Platelet component dose (< 2.9 × 1011) | 1 | 255 | Risk Ratio (M-H, Fixed, 95% CI) | 1.07 [0.66, 1.74] |